$COO (The Cooper Companies Inc.)

$COO {{ '2015-12-17T22:28:22+0000' | timeago}} • Announcement

Medical device company $COO said that CooperSurgical, its women's health care unit, has acquired Research Instruments Limited, a specialist manufacturer and supplier of in-vitro fertilization (IVF) medical devices and systems headquartered in the UK. The transaction is valued at approx. $51MM & is expected to be neutral to EPS in FY16.

$COO {{ '2017-09-11T20:51:49+0000' | timeago}} • Announcement

Medical devices company $COO has signed an agreement with pharma firm $TEVA to acquire the global rights and business of Teva’s Paragard Intrauterine Device for $1.1Bil in cash. The transaction, which is likely to close prior to the end of the calendar year, is expected to be accretive to Cooper's earnings by $0.7-0.75 per share in the first year.

$COO {{ '2017-08-31T20:33:38+0000' | timeago}} • Announcement

$COO expects its 4Q17 total revenue in the range of $552-565MM and its non-GAAP EPS in the range of $2.60-2.70. The company predicts CooperVision revenue in the range of $435-445MM and CooperSurgical revenue to be in the range of $117-120MM for 4Q17.

$COO {{ '2017-08-31T20:31:46+0000' | timeago}} • Announcement

$COO lifted its FY17 total revenue outlook to $2.129-2.142Bil from $2.110-2.135Bil and its non-GAAP EPS guidance to $9.66-9.76 from $9.50-9.65. The company also raised its FY17 CooperVision revenue estimate to $1.67-1.68Bil from $1.645-1.665Bil, while lowering its CooperSurgical revenue forecast to $459-462MM from $465-470MM.

$COO {{ '2017-08-31T20:31:29+0000' | timeago}} • Announcement

$COO reported a jump in 3Q17 earnings driven by favorable product mix and currency within CooperVision as well as improved margins at CooperSurgical from successful integration activity. Net income rose to $103.6MM or $2.09 per share from $87.9MM or $1.79 per share last year. Sales grew 8% to $556MM. Non-GAAP EPS increased 15% to $2.64.

$COO {{ '2017-07-06T20:48:37+0000' | timeago}} • Announcement

$COO has declared a semi-annual dividend of 3 cents per share, payable on August 7, 2017, to stockholders of record on July 21, 2017.

$COO {{ '2017-06-02T11:34:54+0000' | timeago}} • Webcast

$COO stated that on the consumer purchasing trend, the company is seeing solid trends. The biggest driver in the marketplace continues to be the trading up, which means taking the existing consumer base and moving it from the two-week modality into primarily the one-day modality.

$COO {{ '2017-06-02T11:11:33+0000' | timeago}} • Webcast

$COO expects 3Q17 EPS to be slightly lower than 4Q17 due to lower sequential GM at CooperVision. This 3Q17 reduction is due to inventory turns every six months and production level declines in Dec. and Jan. due to annual manufacturing shutdowns to upgrade and retool $COO's plants.

$COO {{ '2017-06-02T11:02:51+0000' | timeago}} • Webcast

$COO's operating expenses grew 8.8% in 2Q17, slightly above the reported revenue growth of 8%. This was driven by investments such as additional sales personnel, along with expenses from acquisition. Operating income growth however was strong, up 18.9%, driven by gross margin improvements. Operating margins grew 2.5% YoY to 26.8%.

$COO {{ '2017-06-02T10:51:59+0000' | timeago}} • Webcast

$COO commented that in the contact lens market overall, the company grew its share two times the market or 10% against the market growth of 5% in calendar first quarter. Geographically, $COO grew 8% in the Americas, 10% in EMEA and 16% in Asia-Pacific.

$COO {{ '2017-06-01T20:38:07+0000' | timeago}} • Announcement

$COO lifted its FY17 total revenue outlook to $2.110-2.135Bil from $2.09-2.13Bil and its non-GAAP EPS guidance to $9.50-9.65 from $9.10-9.30. The company also raised its FY17 CooperVision revenue estimate to $1.645-1.665Bil from $1.62-1.65Bil, while lowering its CooperSurgical revenue forecast to $465-470MM from $470-480MM.

$COO {{ '2017-06-01T20:37:42+0000' | timeago}} • Announcement

$COO reported a jump in 2Q17 earnings driven by higher sales as well as favorable currency and product mix within CooperVision led by Biofinity. Net income rose to $104.9MM or $2.12 per share from $74.1MM or $1.52 per share last year. Net sales grew to $522.4MM from $483.8MM. Non-GAAP EPS increased to $2.50 from $2.05.

$COO {{ '2017-03-21T20:58:25+0000' | timeago}} • Announcement

$COO's Board of Directors has approved a $500MM increase in the company's share repurchase program. The share repurchase program now totals $1Bil and has approximately $618.5MM of remaining availability with no expiration date.

$COO {{ '2017-03-02T21:42:24+0000' | timeago}} • Announcement

$COO said that during 1Q17, CooperVision segment continued gaining market share driven by growth in Biofinity and daily silicone hydrogel products while CooperSurgical segment continued its growth driven by fertility.

$COO {{ '2017-03-02T21:38:18+0000' | timeago}} • Announcement

For FY17, $COO expects total revenue in the range of $2.09-2.13Bil, CVI revenue in the range of $1.62-1.65Bil and CSI revenue in the range of $470-480MM. On a non-GAAP basis, diluted EPS for FY17 is expected in the range of $9.10-9.30.

$COO {{ '2017-03-02T21:32:56+0000' | timeago}} • Announcement

Medical device company $COO reported an increased 1Q17 earnings, driven by higher sales and strong growth in the CooperSurgical and CooperVision segments. Net income rose 47.58% to $75.8MM or $1.53 per share from $51.36MM or $1.05 per share in 1Q16. Revenue for the quarter rose 10.99% to $499.1MM. On an adjusted basis, $COO earned $1.93 per share.

$COO {{ '2017-01-06T14:07:18+0000' | timeago}} • Announcement

$COO has declared a semi-annual dividend of $0.03 per share, payable on February 9, 2017, to stockholders of record on January 23, 2017.

$COO {{ '2016-12-09T12:01:44+0000' | timeago}} • Webcast

$COO said that on the 1-day silicone hydrogel growth expectation for 2017, the company doesn't expect to sustain the 50% that it saw in 2016. On the FX assumptions of major currencies in 2017, $COO stated it expects pretty much today's rates.

$COO {{ '2016-12-09T11:25:02+0000' | timeago}} • Webcast

$COO stated that for FY17, the company expects gross margins to improve to around 64.5%, while operating margin is expected to improve to 25%. On the interest expense side, $COO expects it to be around $28MM for FY17, which includes the additional debt from the Wallace acquisition along with an assumption of 125 BP rate increase.

$COO {{ '2016-12-09T11:05:33+0000' | timeago}} • Webcast

Geographically, $COO said its EMEA region posted a strong quarter in 4Q16, up 12% in constant currency. Growth was driven by Biofinity and 1-day silicone hydrogel franchise. Asia-Pacific region also had a strong quarter, up 13% in constant currency. In Japan, $COO added that its MyDay, Sphere, and Toric launch is progressing well.

$COO {{ '2016-12-09T11:02:16+0000' | timeago}} • Webcast

$COO's CooperVision segment posted strong results in all key areas of its business in 4Q16, resulting in 10% as reported & 11% constant currency revenue growth. This is the fastest CooperVision has grown in 11 qtrs. CooperSurgical also had another strong qtr. posting revenue growth of 20%, while Fertility was the highlight posting a growth of 74%.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
COO (The Cooper Companies Inc.)
Thursday, August 31 2017 - 9:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
XRAY (DENTSPLY International Inc.)
Wednesday, August 9 2017 - 12:30pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
MASI (Masimo Corporation)
Wednesday, August 2 2017 - 8:30pm
STAA (STAAR Surgical Company)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, August 1 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, July 27 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
LH (Laboratory Corp. of America Holdings)
Wednesday, July 26 2017 - 1:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
COO (The Cooper Companies Inc.)
Thursday, June 1 2017 - 9:00pm

AlphaGraphics you may like